General information
CureVac SE
Friedrich-Miescher-Str. 15
72076 Tübingen, Baden-Württemberg
Germany
Contact person: Sarah Fakih, Vice President, Corporate Communications & Investo
Company main phone: +49 (7071) 98830
Website: https://www.curevac.com
Year founded: | 2000
|
Source of foundation: | Spin-off from university |
Name of foundation source: | University of Tuebingen |
No. of employees: |
Worldwide: 904 |
Corporate description / mission:
CureVac SE is is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with expertise in developing, optimizing, and manufacturing this versatile biological molecule for medical purposes. The company has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases.
State of ownership: Private / independent
Headquarters: Yes
IPO (year): 2020
Categorization
Sector: |
- Biotechnology - Therapeutics and Diagnostics
|
Subsector: |
- Anti-infectives
- Antibodies
- Drug delivery
- Immunotherapy
- Nucleic acid drugs
- Vaccines
|
Primary therapeutic areas: |
- Digestive system / gastroenterology
- Diseases of the eye / ophthalmology
- Infectious and parasitic diseases / infectiology / parasitology
- Neoplasms / cancer / oncology
- Respiratory / pulmonology
|
Customer segments: |
- Large biotech & big pharma
- Small biotech
|
Summary Products / Services / Technologies
Number of Biotech Products
Pre-clinical: | 11 | |
Phase I: | 6 | |
Phase II: | 4 | |
Phase III: | 1 | |
Technology used:
RNActive®
RNArt®
RNAntibody®
RNAdjuvant®
Financing details
Fiscal year (end of) 2022
Revenues: | USD 67.42M | |
R&D expenses: | USD 62.55M | |
No. of shares: | 223'883'008 | |
Market cap. / valuation: | USD 2'035.10M | |
Collaborations & Clients
Partnering strategy / collaborations:
Bill & Melinda Gates Foundation
Coalition for Epidemic Preparedness Innovations (CEPI)
CRISPR Therapeutics, etc.